[Pharmacologic therapy of acute coronary syndromes].
Acute coronary syndromes (ACS) are caused by neoinclusive thrombosis of the coronary artery. Arterial atherothrombosis usually results from a cracked atheroma plate and includes platelet and plasmatic component of coagulation. The aim of pharmacological treatment is to influence activated platelets and plasma procoagulant activity. Several clinical studies have demonstrated the benefits of antithrombotic treatment by acetylsalicylic acid, clopidogrel and by blockers of platelet receptors IIb/IIIa. In ACS anticoagulant therapy the non-fractionated heparin are replace ed by low-molecular heparins. The new standard in ACS therapy should become a combination of the acetylsalicylic acid, enoxaparine and clopidogrel. Blockers of platelet receptors IIb/IIIa should be given namely to patients indicated for the early invasive treatment.
Holm
F
F
Kardiologické oddĕlení, Krajská nemocnice Liberec. frantisek.holm@nemlib.cz
Aschermann
M
M
D000208:Acute Disease; D000789:Angina, Unstable / Q000209:etiology; D000925:Anticoagulants / Q000008:administration & dosage*; D003328:Coronary Thrombosis / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D013577:Syndrome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors